Based on the gene editing treatment of wet age-related macular degeneration (BD311) developed based on the BDlenti technology platform, one case of IIT human clinical has been completed.

Wet Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Wet age-related macular degeneration (wAMD) is the growth of new blood vessels behind the retina in the macular area. These new blood vessels are prone to bleeding and fluid leakage, resulting in damage to the macula. wAMD is a kind of advanced macular degeneration. With the development of wAMD, the patient's central vision will quickly lose. The early symptom of wAMD is distortion of vision, which requires thorough and detailed eye examinations.
Gene Therapy For WAMD

BDgene has developed gene therapy drugs for the treatment of wAMD through the BDlenti technology platform. The drug uses a non-integrated lentiviral vector to deliver the anti-vascular endothelial growth factor antibody gene to the fundus, and the antibody will be expressed for a long time to inhibit the proliferation and recurrence of new blood vessels, so as to achieve the purpose of treating wAMD disease.

BDgene's treatment of wAMD is a "one-time administration, long-term antibody expression" gene therapy drug, which is expected to bring bright hope to wAMD patients.

Research And Development Project


Building 10, No.55 Bixi Road, Minhang District, Shanghai,China